References
- Abbasi F, Chu JW, McLaughlin T, et al (2004). Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus. Metabolism, 53, 159-64. https://doi.org/10.1016/j.metabol.2003.07.020
- ADA Guidelines (2012). Executive Summary: Standarts of Medical Care in Diabetes. Diabetes Care v, 35, PAGE?.
- Al-Aubaidy HA, Jelinek HF (2010). 8-Hydroxy-2-deoxyguanosine identifies oxidative DNA damage in a rural prediabetes cohort. Redox Rep, 15, 155-60. https://doi.org/10.1179/174329210X12650506623681
- Anderson D, Yu TW, Wright J, et al (1998). An examination of DNA strand breakage in the comet assay and antioxidant capacity in diabetic patients. Mutat Res, 398, 151-6. https://doi.org/10.1016/S0027-5107(97)00271-6
- Arif M, Islam MR, Hassan F, et al (2010). DNA damage and plasma antioxidant indices in Bangladeshi type 2 diabetic patients. Diabetes Metab, 36, 51-7. https://doi.org/10.1016/j.diabet.2009.05.007
- Assiamira Ferrara, James DL, Charles PQ, et al (2011). Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care, 34, 923-9. https://doi.org/10.2337/dc10-1067
- Bailey CJ, Turner RC (1996). Metformin N Engl J Med, 334, 574-9. https://doi.org/10.1056/NEJM199602293340906
- Bast A, Wolf G, Oberbäumer I, et al (2002). Oxidative and nitrosative stress induces peroxiredoxins in pancreatic beta cells. Diabetologia, 45, 867-76. https://doi.org/10.1007/s00125-002-0846-1
- Bento CF, Pereira P (2011). Regulation of hypoxia-inducible factor 1 and the loss of the cellular response to hypoxia in diabetes. Diabetologia, 54, 1946-56. https://doi.org/10.1007/s00125-011-2191-8
- Bhatia S, Shukla R, Venkata Madhu, et al (2003). Antioxidant status, lipid peroxidation and nitric oxide end products in patients of type 2 diabetes mellitus with nephropathy. Clin Biochem, 36, 557-62. https://doi.org/10.1016/S0009-9120(03)00094-8
- Bonnefont-Rousselot D, Bastard JP, Jaudon MC, et al (2000). Consequences of the diabetic status on the oxidant/antioxidant balance. Diabetes Metab, 26, 163-76.
- Bos R, Zhong H, Hanrahan CF, et al (2002). Levels of hypoxiainducible factor 1 alpha during breast carcinogenesis. J Natl Cancer Res, 93, 309-14.
- Changtao J, Aijuan Q, Tsutomu M, et al (2011). Disruption of Hypoxia-inducible factor 1 in adipocytes improves insülin sensitivity and decreases adiposity in high-fat diet-fed mice. Diabetes, 60, 2484-95. https://doi.org/10.2337/db11-0174
- Currie CJ, Poole CD, Gale EAM (2009). The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. JOURNAL?, 52, 1766-77.
- Del Giudice ME, Fantus IG, Ezzat S, et al (1998). Insulin and related factors in premenopausal breast cancer risk. Breast Cancer Res Treat, 47, 111-20. https://doi.org/10.1023/A:1005831013718
- Dormandy JA, Charbonnel B, Eckland DJ, et al (2005). PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet, 366, 1279-89. https://doi.org/10.1016/S0140-6736(05)67528-9
- Elstner E, Müller C, Koshizuka K, et al (1998). Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA, 95, 8806-11. https://doi.org/10.1073/pnas.95.15.8806
- European Medicines Agency, Committee for medicinal products for human use. (21 July 2011). Pioglitazon Accord, Summary of opinion (initial authorisation), website: www.ema.europa.eu ; e-mail: info@ema.europa.eu
- Evans JM, Donnelly LA, Emslie-Smith AM, et al (2005). Metformin and reduced risk of cancer in diabetic patients. BMJ, 330, 1304-5. https://doi.org/10.1136/bmj.38415.708634.F7
- Feng Z, Zhang H, Levine AJ, et al (2005). The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci USA, 102, 8204-9. https://doi.org/10.1073/pnas.0502857102
- Food and Drug Administration (2010). FDA drug safety communication: ongoing safety review of actos (pioglitazone) and potential increased risk of bladder cancer after two years expose (Internet),
- Fridlyand LE, Philipson LH (2006). Reactive species and early manifestation of insulin resistance in type 2 diabetes. Diabetes Obes Metab, 8, 136-45. https://doi.org/10.1111/j.1463-1326.2005.00496.x
- Gapstur SM, Gann PH, Colangelo LA, et al (2001). Postload plasma glucose concentration and 27-year prostate cancer mortality (United States). Cancer Causes Control, 12, 763-72. https://doi.org/10.1023/A:1011279907108
- Giovannucci E (1995). Insulin and colon cancer. Cancer Causes Control, 6, 164-79. https://doi.org/10.1007/BF00052777
- Govindarajan R, Ratnasinghe L, Simmons DL (2007). Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol, 25, 1476-81. https://doi.org/10.1200/JCO.2006.07.2777
-
Gunton JE, Kulkarni RN, Yim S, et al (2005). Loss of ARNT/HIF1
${\beta}$ mediates altered gene expression and pancreatic-islet dysfunction in human type 2 diabetes. Cell, 122, 337-49. https://doi.org/10.1016/j.cell.2005.05.027 - Hannon-Fletcher MP, O' Kane MJ, Moles KW, et al (2000). Levels of peripheral blood cell DNA damage in insülin dependent diabetes mellitus human subjects. Mutat Res, 460, 53-60. https://doi.org/10.1016/S0921-8777(00)00013-6
- Hardie DG, Hamley SA (2001). AMP-activated protein kinase: the energy charge hypothesis revisited. Bioessays, 23, 1112-9. https://doi.org/10.1002/bies.10009
- Hawley SA, Gadalla AE, Olsen GS, et al (2002). The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes, 51, 2420-5. https://doi.org/10.2337/diabetes.51.8.2420
- Hay N, Sonenberg N (2004). Upstream and downstream of mTOR. Genes Dev, 18, 1926-45. https://doi.org/10.1101/gad.1212704
- James D Lewis, Assiamira Ferrara, Tiffany Peng, et al (2011). Risk of bladder cancer among diabetiv patients treated with pioglitazone. Diabetes Care, 34, 916-22. https://doi.org/10.2337/dc10-1068
- Kemp BE, Stapleton D, Campbell DJ (2003). AMP-activated protein kinase, super metabolic regulator. Biochem Soc Trans, 31:162-8. ndocrine-Related Cancer, 13, 739-49.
- Kimbro K S, Simons JW (2006). Hypoxia-inducible factor-1 in human breast and prostate cancer. Endocrine-Related Cancer, 13, 739-49. https://doi.org/10.1677/erc.1.00728
- Koro C, Barrett S, Qizilbash N (2007). Cancer risks in thiazolidinedione users compared to other anti-diabetic agents. Pharmaco-epidemiol Drug Saf, 16, 485492.
- Kubota T, Koshizuka K, Williamson EA, et al (1998) Ligand for peroxisome proliferator-activated receptor gamma (Troglitazone) has potent antitumor effect against human prostat cancer both in vitro and in vivo. Cancer Res, 58, 3344-52.
- Liang Z, Wu T, Lou H, et al (2004). Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4. Cancer Res, 64, 4302-8. https://doi.org/10.1158/0008-5472.CAN-03-3958
- Lim JH, Lee ES, You HJ, et al (2004). Ras-dependent induction of HIF-1 alpha785 via the Raf/MEK/ERK pathway: a novel mechanism of Ras-mediated tumor promotion. Oncogene, 23, 9427-31. https://doi.org/10.1038/sj.onc.1208003
- Liu H, Zang C, Fenner MH et al (2003). PPARgamma ligands and ATRA inhibit the invasion of human breast cancer cells in vitro. Breast Cancer Res Treat, 79, 63-77. https://doi.org/10.1023/A:1023366117157
- Luiz Gustavo Oliveira Brito, Viviane Fernandes Schiavon, Jurandyr Moreira da Andrade, et al (2011). Expression of Hypoxia-inducible factor 1-α and vascular endothelial growth factor-C in locally advanced breast cancer patients. Clin Sci, 66, 1313-9.
- Martinez-Outschoorn UE, Balliet RM, Rivadeneira DB, et al (2010). Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: A new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. Cell Cycle, 9, 3256-76. https://doi.org/10.4161/cc.9.16.12553
- Mueller E, Sarraf P, Tontonoz P, et al (1998). Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell, 1, 465-70. https://doi.org/10.1016/S1097-2765(00)80047-7
- Musarrat J, Arezina-Wilson J, Wani AA (1996). Prognostic and aetiological relevance of 8-hydroxyguanosine in human breast carcinogenesis. Eur J Cancer, 32A, 1209-14.
- Nathan DM, Buse JB, Davidson MB, et al (2009). American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 32, 193-203. https://doi.org/10.2337/dc08-9025
- Paolo Vigneri, Francesco Frasca, Laura Sciacca, et al (2009). Diabetes and cancer. Endocrine-Related Cancer, 16, 1103-23. https://doi.org/10.1677/ERC-09-0087
- Rathmann W, Giani G (2004). Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care, 27, 2568-9. https://doi.org/10.2337/diacare.27.10.2568
- Rosen P, Nawroth PP, King G, et al (2001). The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev, 17, 189-212. https://doi.org/10.1002/dmrr.196
- Rubenstrunk A, Hanf R, Hum DW, et al (2007). Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta, 1771, 1065-81. https://doi.org/10.1016/j.bbalip.2007.02.003
- Rahimi R, Nikfar S, Larijani B, et al (2005). A review on role of antioxidants in the management of diabetes and its complications. Biomed Pharmacother. 59, 365-73. https://doi.org/10.1016/j.biopha.2005.07.002
- Rikio Y, Masahide M, Yoshihiro S, et al (2003). Expression of peroxisome proliferator activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer, 104, 597-602. https://doi.org/10.1002/ijc.10980
- Sabatini DM (2006). mTOR and cancer: insights into a complex relationship. Nat Rev Cancer, 6, 729-34 https://doi.org/10.1038/nrc1974
- Samuni Y, Cook JA, Choudhuri R, et al (2010). Inhibition of adipogenesis by Tempol in 3T3-L1 cells. Free Radic Biol Med, 49, 667-73. https://doi.org/10.1016/j.freeradbiomed.2010.05.028
- Semenza GL (2010). Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene, 29, 625-34. https://doi.org/10.1038/onc.2009.441
- Suzuki S, Arnold LL, Pennigton KL, et al (2010). Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat. Toxicol Sci, 113, 349-57. https://doi.org/10.1093/toxsci/kfp256
- Talks KL, Turley H, Gatter KC, et al (2000). The expression and distribution of the hypoxia-inducible factors HIF-1 alpha and HIF-2 alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol, 157, 411-21. https://doi.org/10.1016/S0002-9440(10)64554-3
- UK Prospective Diabetes Study (UKPDS) Group (1998). Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet, 352, 854-65. https://doi.org/10.1016/S0140-6736(98)07037-8
- Van Diest PJ, Vleugel Mm, Van der Wall E (2005). Expression of HIF-1 alpha in human tumours. J Clin Pathol, 58, 335-6.
- Van Dyke K, Jabbour N, Hoeldtke R, et al (2010). Oxidative/nitrosative stresses trigger I diabetes: preventable in streptozotocin rats and detectable in human disease. Ann N Y Acad Sci, 1203, 138-45. https://doi.org/10.1111/j.1749-6632.2010.05563.x
- Wu LL, Chiou CC, Chang PY, et al (2004). Urinary 8-OHdG: a marker of oxidative stress to DNA and a risk factor for cancer, atherosclerosis and diabetics. Clin ChimActa, 339, 1-9. https://doi.org/10.1016/j.cccn.2003.09.010
- Wullschleger S, Loewith R, Hall MN (2006). TOR signaling in growth and metabolism. Cell, 124, 471-84. https://doi.org/10.1016/j.cell.2006.01.016
- Zheng F, Lu W, Jia C, et al (2010). Relationships between glucose excursion and the activation of oxidative stress in patients with newly diagnosed type 2 diabetes or impaired glucose regulation. Endocrine, 37, 201-8. https://doi.org/10.1007/s12020-009-9296-6
- Zong H, De Marzo AM, Laughner E, et al (1999). Overexpression of hypoxia-inducible factor1 alpha in common human cancers and their metastases. Cancer Res, 59, 5830-5.
Cited by
- Metformin—mode of action and clinical implications for diabetes and cancer vol.10, pp.3, 2014, https://doi.org/10.1038/nrendo.2013.256
- Metformin reverses multidrug resistance in human hepatocellular carcinoma Bel-7402/5-fluorouracil cells vol.10, pp.6, 2014, https://doi.org/10.3892/mmr.2014.2614
- Gerometabolites: The pseudohypoxic aging side of cancer oncometabolites vol.13, pp.5, 2014, https://doi.org/10.4161/cc.28079
- Diabetes - Increased Risk for Cancers through Chromosomal Aberrations? vol.15, pp.11, 2014, https://doi.org/10.7314/APJCP.2014.15.11.4571
- inhibitors on development of castrate resistance and metastases in prostate cancer vol.3, pp.2, 2014, https://doi.org/10.1002/cam4.189
- Metformin inhibits proliferation and enhances chemosensitivity of intrahepatic cholangiocarcinoma cell lines vol.31, pp.6, 2014, https://doi.org/10.3892/or.2014.3151
- Prognostic value of vascular endothelial growth factor and hypoxia-inducible factor 1α in canine malignant mammary tumors vol.33, pp.5, 2015, https://doi.org/10.3892/or.2015.3856
- Effects of Methylsulfonylmethane (MSM) on exercise-induced oxidative stress, muscle damage, and pain following a half-marathon: a double-blind, randomized, placebo-controlled trial vol.14, pp.1, 2017, https://doi.org/10.1186/s12970-017-0181-z
- Hyperglycemia-Associated Dysregulation of O-GlcNAcylation and HIF1A Reduces Anticancer Action of Metformin in Ovarian Cancer Cells (SKOV-3) vol.19, pp.9, 2018, https://doi.org/10.3390/ijms19092750